Indivior Pharmaceuticals (INDV) Cost of Revenue (2024 - 2026)

Indivior Pharmaceuticals has reported Cost of Revenue for 3 years, with the latest figure at $50.0 million in Q2 2026.

• On a quarterly basis, Cost of Revenue fell 3.85% year-over-year to $50.0 million in Q2 2026; TTM through Jun 2026 was $240.0 million, a 14.29% increase from a year earlier, with the FY2025 full-year figure at $246.0 million, up 6.49% from the prior year.
• Cost of Revenue was $50.0 million for Q2 2026 at Indivior Pharmaceuticals, up from $40.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $83.0 million in Q3 2025, with the low at $38.0 million in Q1 2024.
• Average Cost of Revenue over 3 years is $56.7 million, with a median of $51.0 million recorded in 2025.
• The largest YoY upside for Cost of Revenue was 39.58% in 2025 against a maximum downside of 34.18% in 2025.
• Over 3 years, Cost of Revenue stood at $48.0 million in 2024, then surged by 39.58% to $67.0 million in 2025, then decreased by 25.37% to $50.0 million in 2026.
• The last three Cost of Revenue figures came in at $50.0 million (Q2 2026), $40.0 million (Q1 2026), and $67.0 million (Q4 2025), per Business Quant data.